Objective-Factor XI (FXI) promotes hemostasis and thrombosis through enhancement of thrombin generation and has been shown to play a critical role in the formation of occlusive thrombi in arterial injury models. The aim of this study was to investigate the mechanisms governing interactions between FXI and platelets. Methods and Results-Platelet adhesion to immobilized FXI was abrogated in the presence of the low-density lipoprotein (LDL) receptor antagonist, receptor-associated protein (RAP), soluble recombinant apolipoprotein E receptor 2 (ApoER2), or the LDL-binding domain 1 or 2 of ApoER2. FXI supported wild-type murine platelet binding; in contrast, ApoER2-deficient murine platelets did not adhere to FXI. In the presence of shear, platelet aggregates formed on FXI or activated FXI (FXIa) surfaces, whereas the presence of RAP, binding domain 1 of ApoER2, or an anti-GPIb␣ mAb blocked platelet adhesion to FXI or FXIa under shear. Soluble FXI bound to immobilized ApoER2Ј with an affinity of 61 nmol/L. Conclusions-This study has identified apolipoprotein E receptor 2 (ApoER2, LRP8), a member of the LDL receptor family, as a platelet receptor for FXI. The interaction of FXI with other cell types that express ApoER2 remains to be explored. (Arterioscler Thromb Vasc Biol. 2009;29:1602-1607.)
F actor XI (FXI) is a 160 kDa glycoprotein that participates in the intrinsic blood coagulation pathway and contributes to hemostasis. Activated FXI (FXIa) is a serine protease generated by cleavage of FXI at the Arg 369 -Ile 370 bond by activated factor XII, thrombin, or via autocatalytic activation. 1 FXIa contributes to sustained thrombin generation via activation of factor IX (FIX). 2 Inherited FXI deficiency causes a mild bleeding diathesis and is protective against ischemic stroke, 3, 4 whereas an elevated FXI plasma level is an independent risk factor for thrombotic diseases such as deep vein thrombosis. 5 Consistent with these observations, FXI plays a critical role in experimental thrombus growth in rabbits, mice, and primates. 6 -10 See accompanying article on page 1409 FXI circulates as a disulfide-linked homodimer in complex with plasma high molecular weight kininogen (HK). FXI shares high sequence homology (58% amino acid identity) with the functionally-distinct plasma protein prekallikrein, which also circulates in complex with HK. 11, 12 Although the serine protease domain of each FXI subunit is similar to catalytic domains for other coagulation proteases, the noncatalytic portion contains 4 apple domains (A1 to A4), a feature shared only with prekallikrein. 12, 13 The FXI A3 domain has been shown to contain binding sites for FIX and for the platelet receptor glycoprotein Ib-IX-V (GPIb). 14, 15 FXI binding has been localized to the leucine-rich repeat (LRR) sequences on the NH 2 -terminal globular domain of GPIb␣, at a site distinct from the anionic thrombin-binding domain of GPIb␣. 16, 17 It is unknown whether FXI-platelet binding is solely mediated by GPIb␣ or whether other platelet receptor(s) exist that can support interactions with FXI.
GPIb␣ has been shown to form a complex on the platelet surface with apolipoprotein E receptor 2 (ApoER2, LRP8), 18 -20 a member of the low-density lipoprotein (LDL) family of receptors. ApoER2 initiates intracellular signaling through the adaptor protein disabled-1 (Dab-1) in platelets. 21 The extracellular domain of ApoER2 consists of 3 regions: (1) the type A-binding repeats of LDL-binding domains displaying a negatively-charged surface, which are responsible for receptor-ligand interactions; (2) type B repeats, which are homologous to regions in the epidermal growth factor precursor; and (3) the protein stack of O-linked sugar domains that separate the LDL-binding domains from the cellular surface. We have recently shown that platelet and leukocyte ApoER2 mediate interactions with the anticoagulant serine protease, activated protein C. 22, 23 Here, we present the first evidence that identifies FXI as a ligand for ApoER2.
Materials and Methods

Reagents
Plasma-derived FXI, FXIa, and FXa were purchased from Hematologic Technologies Inc, fibrinogen and high molecular weight kininogen were from Enzyme Research Laboratories Inc, fibrillar collagen was from Chrono-Log Corporation, and AK2 was from GeneTex Inc. Soluble GPIb␣, ApoER2Ј (a splice variant of ApoER2 lacking LDL-binding domains 4, 5, and 6), LDL-binding domains 1 and 2 of ApoER2, plasma-derived ␤2GPI, and dimeric ␤2GPI were cloned, expressed, and purified as described. 19,24 -27 HRP-labeled anti-FXI antibody was purchased from diaPharma. Mouse anti-FXI mAb has been described previously, 28 and HRP-conjugated rabbitantimouse IgG was from Dako. All other reagents were from Sigma-Aldrich Inc or previously named sources. 29, 30 
Preparation of Human and Murine Platelets and Red Blood Cells
Human venous blood was drawn by venipuncture from healthy volunteers into sodium citrate (final concentration 0.38% vol/vol) and acid/citrate/dextrose (ACD, 10% vol/vol). Platelet-rich plasma (PRP) was prepared by centrifugation of whole blood at 200 g for 20 minutes. The platelets were then isolated from PRP by centrifugation at 1000 g for 10 minutes in the presence of prostacyclin (0.1 g/mL). After centrifugation steps, purified human platelets were resuspended in modified Tyrode buffer (129 NaCl mmol/L, 0.34 mmol/L Na 2 HPO 4 , 2.9 mmol/L KCl, 12 mmol/L NaHCO 3 , 20 mmol/L HEPES, 5 mmol/L glucose, 1 mmol/L MgCl 2 ; pH 7.3) as previously described. 29 After the removal of PRP, red blood cells were pelleted at 2000 g for 10 minutes at 25°C. Red blood cells were subsequently washed 3 times with red blood cell buffer (10 mmol/L HEPES, 140 mmol/L NaCl, 5 mmol/L glucose, pH 7.4) as previously described. 29 Mice deficient in ApoER2 were purchased from the Jackson Laboratory (Bar Harbor, Maine). Murine blood was drawn from CO 2 terminally-anesthetized mice into ACD at a ratio of 1:10. PRP was obtained by centrifugation at 200 g for 6 minutes. Washed platelets were prepared via centrifugation of PRP at 1000 g in the presence of prostacyclin (0.1 g/mL) for 6 minutes. The pellet was resuspended in modified Tyrode buffer to the desired platelet count. All animals were maintained using housing and husbandry in accordance with institutional regulations.
Static Adhesion Assays
Glass coverslips were incubated with a 50 g/mL solution of FXI, FXIa, or fibrinogen for 1 hour at room temperature. Surfaces were then blocked with denatured fatty acid-free bovine serum albumin (BSA, 5 mg/mL) for 1 hour and washed with phosphate-buffered saline (PBS). Purified human platelets (2ϫ10 7 /mL) were incubated on protein-coated coverslips at 37°C for 45 minutes. Platelet spreading was imaged using Köhler illuminated Nomarski differential interference contrast (DIC) optics with a Zeiss 63ϫ oil immersion 1.40 NA plan-apochromat lens on a Zeiss Axiovert 200m microscope (Carl Zeiss). The degree of adhesion was computed using Image J software. 31
Solid Phase Binding Assays
Soluble ApoER2Ј (sApoER2Ј; 5 g/mL) was coated on Corning Costar 2595 protein assay plates as previously described. 22 Coated wells were blocked with BSA for 1 hour at room temperature. Wells were washed 4 times with washing buffer (PBS with 0.1% tween-20). Prescribed dilutions of human FXI (0 to 200 nmol/L) in the absence or presence of 40 g/mL RAP were added to the wells for 1 hour at room temperature. To detect ApoER2Ј-bound FXI, plates were incubated with a mouse antihuman FXI mAb (1 g/mL) for 1 hour before washing and incubation with an HRP-labeled rabbit antimouse antibody. The assay was developed by addition of TMB (100 L/well) followed by acid stop with 1 mol/L H 2 SO 4 , and changes in absorbance at 450 nm were measured. The apparent ⌲ d value was obtained from the binding data using Prism 4 software (GraphPad Software Inc).
Flow Adhesion Assays
Glass capillary tubes were incubated for 1 hour at room temperature with a solution of 50 g/mL of either FXI or FXIa. Tubes were then washed with PBS, followed by incubation with 5 mg/mL denatured BSA for 1 hour. Tubes were then incorporated into a flow system on the stage of a Zeiss Axiovert microscope (Carl Zeiss). Reconstituted blood (autologous packed red blood cells reconstituted with washed platelets in modified Tyrode buffer at a final concentration of 3ϫ10 8 platelets/mL, 50% vol/vol) was perfused through the chamber for 3 minutes at a wall shear rate of 600 s Ϫ1 . Platelet interactions were imaged in real time with a Zeiss AxioCam.
Analysis of Data
Data are shown as meansϮSEM. Statistical significance of differences between means was determined by ANOVA. If means were shown to be significantly different, multiple comparisons were performed by the Tukey test. Probability values of PϽ0.05 were selected to be statistically significant.
Results
Platelets Bind to and Spread on Factor XI
We sought to investigate the ability of FXI to support platelet adhesion and spreading. The interaction of purified platelets with surface-immobilized FXI was monitored in real-time using DIC microscopy. As shown in Figure 1A , adhesion of platelets to immobilized FXI was followed by a series of characteristic changes in platelet morphology over a 20-minute time course resulting in the formation of large, sheet-like lamellipodia. Consistent with previous reports, surface-immobilized fibrinogen was also able to support platelet adhesion and spreading ( Figure 1A ). Fluorescent labeling of the actin cytoskeleton revealed that stress fibers were formed in fully spread platelets on FXI ( Figure 1B ). Real-time imaging of platelets loaded with the calcium-reporter dye, Oregon Green BAPTA 1-AM, showed that platelets interacting with FXI demonstrated an initial Ca 2ϩ release followed by a delay of up to 5 minutes, after which a further increase in intracellular calcium occurred that oscillated over 3 to 7 minutes before declining ( Figure 1C ). On fibrinogen, platelets displayed an initial Ca 2ϩ spike that oscillated in a descending manner over the 12 minutes shown ( Figure 1C ). A similar degree of platelet spreading, actin reorganization, and intracellular calcium mobilization was recorded for platelets on immobilized FXIa (supplemental Figure I , available online at http://atvb.ahajournals.org).
We next aimed to determine the intracellular mechanisms that facilitate platelet spreading on FXI. Presence of an ADP scavenger (apyrase, 2 U/mL) with a cyclooxygenase inhibitor (indomethacin, 10 mol/L) reduced platelet adhesion and spreading on FXI surfaces (supplemental Figure II) . Treatment of platelets with inhibitors to Src kinases (PP2, 20 mol/L), PI3-kinases (wortmannin, 100 nmol/L) or an intracellular Ca 2ϩ chelator (BAPTA-AM, 10 mol/L) inhibited platelet spreading on immobilized FXI (supplemental Figure II) . Similar results were seen on FXIa surfaces (supplemental Figure II) .
ApoER2 Mediates Platelet Adhesion to FXI
FXI has been shown to bind specifically and reversibly to high affinity sites on the platelet surface. To characterize the molecular mechanisms of platelet-FXI binding, adhesion assays were performed in the presence of receptor-associated protein (RAP), which universally inhibits ligand binding to the LDL receptor family. Our data show that RAP eliminated platelet binding to immobilized FXI, but not to fibrinogen ( Figure 2 ). Furthermore, the presence of soluble recombinant ApoER2Ј (sApoER2Ј) abrogated platelet binding to FXI (Figure 2) . Moreover, the presence of the LDL-binding domain 1 or 2 of ApoER2 reduced platelet adhesion to FXI by 78% and 55%, respectively ( Figure 2B ).
To verify the ability of ApoER2 to mediate platelet binding to FXI, platelets from wild-type C57Bl/6 or ApoER2-deficient mice were incubated over surfaces coated with FXI or fibrinogen. As shown in Figure 3 , a greater than 90% reduction in platelet adhesion on FXI was observed for ApoER2deficient platelets compared to wild-type (13.6Ϯ1.4 versus 1.2Ϯ0.5ϫ10 2 platelets/mm 2 on FXI for wild-type versus ApoER2 Ϫ/Ϫ , respectively). A similar level of reduction in binding was observed for wild-type platelets in the presence of binding domain 1 of ApoER2 (Figure 3) . The presence of soluble GPIb␣ (40 g/mL) did not affect wild-type platelet binding to immobilized FXI (data not shown). Equivalent levels of adhesion were observed on fibrinogen for wild-type and ApoER2 Ϫ/Ϫ platelets (155Ϯ15 versus 150Ϯ12ϫ10 2 platelets/mm 2 on fibrinogen for wild-type versus ApoER2 Ϫ/Ϫ , respectively).
Mechanisms of FXI-Platelet Interactions Under Flow
To evaluate the interaction between platelets and FXI in the presence of shear, washed human platelets were reconstituted with purified red blood cells (50% vol/vol, final platelet count 3ϫ10 8 /mL) and perfused over immobilized FXI for 3 minutes at 600 s Ϫ1 . In the presence of shear, platelets in reconstituted blood formed aggregates on immobilized FXI (Figure 4) .
Addition of the anti-GPIb␣ mAb, AK2, or LDL-binding domain 1 of ApoER2 blocked platelet adhesion to FXI under shear conditions (Figure 4) . Similar results were observed on FXIa surfaces in the presence of shear (Figure 4 ).
Effects of Zn 2؉ and HK on Platelet Adhesion to FXI Surfaces
FXI circulates in the plasma in complex with HK, and earlier studies have shown that FXI-platelet interactions in solution require both HK and the divalent cation, Zn 2ϩ . 32, 33 As shown in Figure 5A , FXI surfaces supported platelet adhesion in the presence of either vehicle or the combination of Zn 2ϩ and HK. The presence of RAP abrogated platelet adhesion to FXI in the absence or presence of Zn 2ϩ and HK ( Figure 5A ). The degree of platelet adhesion to surfaces of the active site mutant FXI-Ala557, which lacks proteolytic activity, in the presence of vehicle was similar to adhesion to surfaces of native FXI (31.4Ϯ4.2 versus 33.9Ϯ3.6ϫ10 2 platelets/mm 2 on FXI-Ala557 versus native FXI, respectively).
FXIa surfaces supported platelet adhesion either in the presence of vehicle or the combination of Zn 2ϩ and HK. Addition of RAP significantly, but incompletely, inhibited platelet adhesion to FXIa in the absence or presence of Zn 2ϩ and HK ( Figure 5A ). The remaining platelet adhesion on FXIa in each case was eliminated in the presence of RAP in combination with the serine protease inhibitor, D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK, 40 mol/L).
Effects of Known ApoER2 Ligands on Platelet Adhesion to FXI
ApoER2 has been shown to bind to plasma components such as antiphospholipid antibody-dimerized beta 2 glycoprotein I (␤ 2 GPI) and activated protein C (APC). 19, 22 As shown in Figure  5B , platelet adhesion to FXI was unaffected by the presence of either plasma-derived or dimerized ␤ 2 GPI. Conversely, platelet adhesion to immobilized FXIa or APC was significantly reduced in the presence of dimeric ␤2GPI ( Figure 5B ). Platelet adhesion to FXI or FXIa was not inhibited by the presence of APC in solution (data not shown).
Evaluation of Soluble FXI Binding to Purified sApoER2
To quantify direct binding of FXI to ApoER2, prescribed dilutions of FXI were incubated with immobilized sApoER2Ј, and the level of bound FXI was determined using anti-FXI antibodies as described in Materials and Methods. As shown in Figure 6 , soluble FXI bound to immobilized sApoER2Ј with an apparent affinity of 61 nmol/L. The presence of RAP significantly reduced FXI binding to sApoER2Ј ( Figure 6 ). Taken together, our data identify ApoER2 as a novel receptor for FXI.
Discussion
The aim of this study was to investigate the molecular mechanisms of FXI-platelet interactions. We identified FXI as a novel ligand for the receptor ApoER2. Our initial data demonstrated that purified recombinant forms of ApoER2 abrogated platelet binding to FXI, and that platelets from ApoER2-deficient mice did not adhere to immobilized FXI. Immobilized ApoER2Ј specifically bound FXI in a cell-free assay with an affinity of 61 nmol/L. Our data identify FXI as a ligand for the platelet receptor ApoER2.
FXI binding to platelets was first described more than 30 years ago. 34 GPIb␣ was identified as the major receptor for FXI on activated platelets, 16, 17, 35 but studies have failed to show that GPIb␣ mediates FXIa binding to activated platelets under static conditions. 36, 37 The data reported here support a role for GPIb␣ in mediating shear-dependent interactions between quiescent platelets and both FXI and FXIa. The reason for the discrepancy between our results and earlier studies is not clear, but it is noteworthy that ApoER2Ј has been shown to colocalize with the GPIb/IX/V complex on the platelet surface. 19 As FXI and FXIa exist as homodimers, perhaps one FXI/FXIa molecule can simultaneously bind both GPIb␣ and ApoER2Ј on the platelet surface. Because ApoER2 is expressed on the platelet surface at far lower levels than the GPIb complex, 19 this may explain why a total of only 1500 FXI binding sites per platelet have been reported, 33 even though GPIb is present at 25 000 copies per platelet. 38 Since the discovery of ApoER2 on platelets in 1999, platelet ApoER2 has been shown to bind a handful of plasma components. 19, 22, 39, 40 Data reported here suggest that FXI has a similar affinity for ApoER2 as recently-described ligands such as dimeric ␤ 2 GPI and activated protein C (APC). 22, 41 Autoantibodies to ␤ 2 GPI correlate highly with recurrent arterial thrombosis and fetal loss associated with antiphospholipid antibody syndrome (APS). 21 The in vitro properties of APS patient ␤ 2 GPI-anti-␤ 2 GPI antibody complexes are mimicked by dimeric ␤ 2 GPI. 27 Although neither dimeric ␤ 2 GPI nor APC in our experiments inhibited platelet adhesion to FXI, the presence of dimeric ␤ 2 GPI significantly reduced platelet adhesion to immobilized FXIa. ␤ 2 GPI has been shown to inhibit the activation of FXI by FXIIa and thrombin, whereas cleavage of ␤ 2 GPI at Lys 317 -Lys 318 by FXIa eliminates this inhibitory effect. 42 Because ␤ 2 GPI is able to interact directly with FXI and FXIa, and FXIa is able to cleave ␤ 2 GPI, further studies are required to determine the exact mechanisms leading to the differential effects of dimeric ␤ 2 GPI on platelet binding to FXI and FXIa. 42, 43 Perhaps the platelet receptor ApoER2 plays a role in mediating the interaction of ␤ 2 GPI with FXI on the surface of activated platelets and subsequent FXIa-mediated proteolytic cleavage of ␤ 2 GPI. It remains to be determined whether deregulation of this process by autoantibodies to ␤ 2 GPI may be an important mechanism for thrombosis in patients with APS.
Although the universal LDL-receptor ligand-binding inhibitor RAP abolished platelet adhesion to FXI, its presence significantly but incompletely inhibited platelet adhesion to FXIa. Previous studies have shown that the catalytic domain of FXIa is involved in platelet interactions. 44 In this study, the remaining platelet adhesion to FXIa was eliminated with the addition of the serine protease inhibitor, PPACK, in combination with RAP. A parallel set of observations was made in the presence of HK/Zn 2ϩ . Taken together, these data point to a possible role for the catalytic domain in platelet-FXIa interactions, suggesting that a distinct RAP-insensitive site exists on the platelet surface that is capable of interacting with FXIa. One such possibility is that FXIa is capable of cleaving PAR receptors. Perhaps FXIa, once bound to the platelet surface via ApoER2, contributes to platelet activation via proteolytic cleavage of platelet PAR receptors. It remains to be determined whether FXI binding to monocytes and endothelial cells, which express ApoER2, 22, 23 is mediated by ApoER2, and whether FXIa ligation of ApoER2 promotes a Reelin-like signaling pathway in these cells.
Recent findings by Tucker et al support the hypothesis that FXI activity is necessary for thrombus stability, as inhibition of FXI led to instability and dissolution of platelet-rich thrombi in a nonhuman primate thrombosis model. 45 FXIa bound to activated platelets has been shown to be resistant to inhibition by exogenous protease nexin 2. 36 It could be that ApoER2Ј, in concert with GPIb␣, plays a critical role in localizing FXI/FXIa to the growing platelet plug, subsequently facilitating FXIa activation of FIX, accelerating thrombin formation, and thus promoting thrombus stability. Future work will be focused on identifying the significance of ApoER2 in FXI-dependent thrombus formation. 
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